SNIPR Advances SNIPR001 Into Phase 2 for E. coli Prevention
COPENHAGEN, Denmark — September 17, 2026 SNIPR announced that the first patient has been enrolled in Part 2 of...
microbiome
Advertisement
Superbrewed Food Launches Shelf-Stable Thryvia Postbiotic
New Castle, Delaware, August 19, 2026 Superbrewed Food, Inc. has announced the commercial launch of Thryvia™, a shelf-stable, protein-derived...
Intelligent Bio Solutions Completes Clinical Study for FDA 510(k) Submission
NEW YORK, August 11, 2026 Intelligent Bio Solutions Inc. announced the completion of its multi-site Method Comparison Study for...
SNIPR Advances SNIPR001 With Compassionate-Use Clinical Evidence
COPENHAGEN, Denmark, August 12, 2026 SNIPR announced new clinical evidence supporting the translational potential of SNIPR001, its engineered CRISPR-enhanced...
Vedanta Biosciences Secures $60M to Advance Phase 3 VE303
CAMBRIDGE, Mass., August 6, 2026 Vedanta Biosciences announced it has secured $60 million in funding to accelerate development of...
Advertisements
Keenova Publishes New XIAFLEX Data in Peyronie’s Disease
Dublin, Ireland, August 3, 2026 Keenova Therapeutics plc announced the publication of a new manuscript evaluating XIAFLEX® (collagenase clostridium...
Acurx Gains FDA Guidance for Ibezapolstat Phase 3 Program
Staten Island, New York, August 3, 2026 Acurx Pharmaceuticals, Inc. announced further regulatory guidance from the U.S. Food and...
City of Hope Unveils AI and Cancer Breakthroughs at AACR
LOS ANGELES, April 16, 2026 City of Hope announced that its scientists will present groundbreaking research findings on cancer...
Boston Scientific to Acquire Nalu Medical for Pain Therapy Expansion
Marlborough, MA – October 17, 2025 – Boston Scientific Corporation announced that it has entered into a definitive agreement...
FDA Fast Tracks Enterome’s OncoMimics™ Cancer Immunotherapy EO2463
Paris, France – October 16, 2025 – The U.S. Food and Drug Administration (FDA) has granted Fast Track designation...
Advertisement
